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KEY POINTS 56 
Question 57 
Does baseline whole body MRI detect asymptomatic cancers at a curable stage in 58 
germline TP53 mutation carriers? 59 
Findings 60 
Using a meta-analysis of 13 cohorts including 578 participants, the overall detection 61 
rate for previously unrecognized new localized malignancies by a single baseline 62 
WBMRI in TP53 mutation carriers was 7% (95% confidence intervals 5-9%). The 63 
false positive rate was 43%. All screen-detected new cancers were treated with 64 
curative intent. 65 
Meaning 66 
Baseline evaluation with whole body MRI offers important clinical utility in 67 
management of cancer risk in TP53 mutation carriers. 68 
 69 
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ABSTRACT  80 
Importance 81 
There are limited guidelines for clinical management in Li-Fraumeni syndrome, a 82 
multi-organ cancer predisposition condition. Whole body magnetic resonance 83 
imaging may play a role in surveillance of this high risk population. 84 
Objective 85 
To assess the clinical utility of whole body magnetic resonance imaging in germline 86 
TP53 mutation carriers at baseline. 87 
Data Sources 88 
Clinical and research surveillance cohorts were identified through the Li-Fraumeni 89 
Exploration Research Consortium. 90 
Study selection 91 
Cohorts that incorporated whole body magnetic resonance imaging for individuals 92 
with germline TP53 mutations were included. 93 
Data extraction and synthesis 94 
Data was extracted by investigators from each cohort independently and synthesized 95 
by two investigators. Random effects meta-analysis methods were used to estimate 96 
proportions.  97 
Main outcomes and measures 98 
The proportion of participants at baseline in whom a lesion was detected that required 99 
follow up and in whom a new primary malignancy was detected.  100 
Results 101 
A total 578 participants from 13 cohorts were included in the analysis. Two hundred 102 
twenty-five lesions requiring clinical follow up were detected by whole body 103 
magnetic resonance imaging in 173 participants. Sixty-one lesions were diagnosed in 104 
 5 
54 individuals as either benign or malignant neoplasms. Overall, 42 cancers were 105 
identified in 39 individuals, with 35 new localized cancers treated with curative 106 
intent. The overall detection rate for new localized primary cancers was 7% (95% 107 
Confidence Interval 5-9%). 108 
Conclusions and relevance 109 
These data suggest clinical utility in baseline whole body magnetic resonance imaging 110 
in TP53 germline mutation carriers, and may form an integral part of baseline clinical 111 
risk management in this high-risk population. 112 
 113 
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  118 
 6 
INTRODUCTION   119 
Li-Fraumeni syndrome (LFS) was first described in 1969 as a highly penetrant 120 
cancer-prone syndrome.
1
 Formal diagnostic criteria for LFS have subsequently been 121 
developed, based on a family or personal history of a broad spectrum of early onset 122 
cancers, including sarcoma, breast cancer, adrenocortical carcinoma and brain tumors, 123 
often with more than one cancer per affected individual.
2-5
 Lifetime cancer risks are 124 
reported to approach 100% for both sexes in cases identified by family history.
6-8
 The 125 
exceedingly high cancer risk in LFS often confers a high psychological and medical 126 
burden.
9
 Pathogenic variants in the tumor suppressor gene, TP53, were first identified 127 
and subsequently found to cause about 70% of classic LFS in 1990.
10,11
 
12,13
 128 
Identification of germline TP53 mutation carriers has increased with increased 129 
sequencing of both germline and somatic DNA using gene panels, whole exome, and 130 
whole genome testing, due, in part, to the influence of precision medicine initiatives.  131 
 132 
Although the clinical characteristics and molecular basis for LFS have been known 133 
for decades, no universally accepted approach exists for risk management. Current 134 
guidelines focus on breast cancer risk primarily because organ-specific surveillance 135 
measures,
14-16
 such as breast magnetic resonance imaging (MRI), are already widely 136 
used for screening in cognate high risk syndromes. However, because breast cancer 137 
constitutes only a proportion of the surgically resectable cancers to which TP53 138 
mutation carriers are prone, there is a need for novel effective methods for cancer 139 
surveillance across a broad range of body or corporal sites. Recently, emerging 140 
studies suggest improved clinical outcomes for TP53 mutation carriers with intensive 141 
screening. The Toronto protocol, which incorporates whole body MRI (WBMRI) 142 
amongst other modalities, was associated with improved survival.
17
 Neonatal 143 
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screening for the Brazilian TP53 founder mutation resulted in adrenocortical tumours 144 
being detected at an early, more curable stage.
18
 Notably, a recent UK study detected 145 
malignancies in 14% of TP53 mutation carriers at baseline WBMRI.
19
 Psychological 146 
benefit has also been reported from participation in a LFS surveillance program.
20
 147 
However, in part because of the rarity of LFS, definitive evidence for the benefits of 148 
screening remain lacking. 149 
 150 
To generate evidence for the efficacy of WBMRI as a surveillance tool for carriers of 151 
pathogenic germline TP53 mutations, we report here a meta-analysis of 13 152 
prospective cohorts conducted in six countries. We assessed the detection rates of 153 
asymptomatic cancers  using WBMRI as part of baseline assessment of TP53 154 
mutation carriers, measured by the rate of identification of investigable lesions and 155 
new primary cancers that can be treated with curative intent. 156 
 157 
 158 
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METHODS  160 
Study Selection  161 
Clinical and research surveillance cohorts were identified through the Li-Fraumeni 162 
Exploration Research Consortium.
21
 Cohorts formed over the past 15 years that 163 
performed WBMRI in individuals at any age were considered (Table 1 in the 164 
Supplement).  All research cohorts had ethical approval and written consent was 165 
obtained from participants or guardians as appropriate. There was no requirement for 166 
subjects to be newly diagnosed for participation in any of the studies included in this 167 
meta-analysis. All cohorts included brain in the WBMRI scan with the exception of 168 
the Huntsman Cancer Institute. All participants were asymptomatic at the time of the 169 
baseline scan. The details of imaging protocols for contributing cohorts, including the 170 
use of contrast and organ-specific sequences, are given in Tables 3-14 in the 171 
Supplement. All participants were known carriers of pathogenic TP53 mutations or 172 
were obligate carriers by pedigree.  173 
 174 
Data Extraction and Classification 175 
Data was extracted by investigators from each cohort and synthesised by two 176 
investigators (MB and DT). Lesions were considered investigable if further clinical 177 
follow up was required in the opinion of the study investigator, including additional 178 
imaging or biopsy. The true positive rate for WBMRI was defined as the rate of 179 
detection of localized, primary cancers that were treated with curative intent. False 180 
positive lesions were defined as considered initially neoplastic (All neoplasms in 181 
Figure 1), but which subsequently were determined on further investigation to be 182 
either benign tumors, recurrences of previous cancers, or incurable metastatic cancers. 183 
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Low grade gliomas were classified as malignant. The treatment intent (curative or 184 
palliative) following diagnosis was recorded in each case. 185 
 186 
Statistical Analysis 187 
Random-effects meta-analysis methods
22
 for proportions were used to aggregate the 188 
data from the 13 participating cohorts. Meta-analyses were performed to estimate the 189 
proportion of participants found to have one or more investigable lesions, the 190 
proportion of participants found to have one or more new primary cancers, and the 191 
proportion of investigable lesions determined to be new primary cancers, with 192 
approximate 95% confidence intervals.
23
 The between-cohort heterogeneity 𝜏2, along 193 
with associated p-value, was estimated using the DerSimonian-Laird method. A logit 194 
transformation was used to calculate the overall proportions. Cohort participants were 195 
additionally subdivided by sex and by age group (0-17, 18-40, or >40 years of age) to 196 
identify age-dependent trends in cancer detection rates and to be consistent with prior 197 
management recommendations.
17
 Tests of subgroup differences were conducted using 198 
Cochran's Q test. All analyses were performed with R version 3.3.1,
24
 using version 199 
4.6-0
25
 of the meta package. 200 
  201 
 202 
  203 
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RESULTS 204 
Research Surveillance Study characteristics 205 
This meta-analysis included 578 participants (376 female) with deleterious germline 206 
TP53 mutations from 13 cohorts who underwent baseline WBMRI between January 207 
1, 2004 and October 1, 2016, (Table 1 in the Supplement). Of these, 134 (77 female) 208 
were 0-17 years of age, 246 (164 female) were 18-40 and 198 (135 female) were >40 209 
years of age. Germline TP53 variant data available for participants showed 183 210 
unique events, including 91 missense, 26 nonsense, 8 frameshift and 20 intronic 211 
variants.  There were a further 38 insertions or deletions. Almost half of the 212 
participants (280/578, of whom 211 were female) had been diagnosed with at least 213 
one prior malignancy. Of the 264 female participants older than 17 years for whom 214 
information was available, 17 (6%) had a single mastectomy, and 110 (42%) had a 215 
double mastectomy.  216 
 217 
A flowchart outlining the disposition of participants included in the meta-analysis is 218 
given in Figure 1. Of the 578 participants, 225 lesions requiring further investigation 219 
were observed in 173 participants. 42 malignant lesions were diagnosed in 39 220 
individuals, with the majority of diagnoses based on biopsy. Four of the 42 malignant 221 
lesions were brain tumors diagnosed on imaging alone. Of the new malignancies, 35 222 
localized primary cancers were diagnosed in 34 individuals, all of whom were treated 223 
with curative intent. The false positive rate, defined here as the proportion of 224 
suspected neoplasms that turned out to be either benign, recurrences of pre-existing 225 
cancers, or newly diagnosed metastatic cancers, was 26/61 (43%). 226 
 227 
Meta-Analysis results 228 
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Figure 1 in the Supplement presents the meta-analysis for the proportion of 229 
participants found to have one or more investigable lesions by WBMRI. Overall, 31% 230 
(95% confidence interval (CI) 26-35%) of participants were determined to have one 231 
or more investigable lesions. No gender differences were detected (p=0.9, Cochran’s 232 
Q). The proportion of investigable lesions identified tended to increase with age 233 
(29%, 30%, 34% for those less than 18, 18-40 and >40 years of age respectively), but 234 
this increase was not statistically significant (p=0.6 overall, Cochran’s Q).  235 
 236 
Figure 2 in the Supplement presents the meta-analysis of the proportion of individuals 237 
in whom one or more new cancers was diagnosed. Overall, 7% (95% CI 5-9%) of 238 
participants were determined to have one or more new primary malignancies. There 239 
was no significant difference between males and females (p=0.4, Cochran’s Q). The 240 
proportion of cancers identified increased with age in males (10%, 10%, 15% 241 
respectively in 0-17, 18-40, >40); females experienced a mid-life reduction in 242 
malignancies detected by WBMRI (15%, 8%, 10%), but neither trend was statistically 243 
significant (p=0.3 for females, p=0.6 for males, Cochran’s Q). A meta-analysis of the 244 
proportion of investigable lesions subsequently identified as a new primary cancer is 245 
given in Figure 3 in the Supplement. Overall, 18% (95% CI 12-27%) of investigable 246 
lesions identified by WBMRI were determined to be new primary cancers, with no 247 
gender difference (p=0.5, Cochran’s Q). The proportion of cancers identified was 248 
highest in 0-17 year olds (31%, 16%, 18% respectively in 0-17, 18-40, >40 year old 249 
participants), but this trend was not statistically significant (p=0.15 overall, Cochran’s 250 
Q). 251 
 252 
Clinical spectrum of new primary cancers detected by WBMRI 253 
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The 35 new primary cancers identified by baseline WBMRI occurred in 34 254 
participants (one 45 year old female with a synchronous localised chromophobe renal 255 
cell carcinoma and a localised uterine leiomyosarcoma). No new primary cancers 256 
were clinically metastatic at diagnosis. The patterns of cancers observed vary by age 257 
and gender (Table 1). All seven bone sarcomas were observed in participants under 258 
40 years of age, with no gender difference, while five of seven soft-tissue sarcomas 259 
arose in participants over the age of 40 years. A single adrenocortical tumor was 260 
found in a child, as was a choroid plexus carcinoma. The diversity of cancers to which 261 
TP53 mutation carriers are prone was evident. Other cancers identified included 262 
carcinomas of the lung (4 participants, all over 40 years of age), kidney (17 year old 263 
female, 24 year old female and a 45 year old female), thyroid (two females 17 and 40 264 
year of age), prostate (two males 41 and 46 years of age), and bowel (21 year old 265 
male). We only observed two breast cancers (a ductal carcinoma in situ in a 49 year 266 
old female, and an invasive ductal carcinoma in a female, 66 years of age). This may 267 
reflect the high rate of mastectomies and/or prior breast cancer diagnoses in the 268 
female population undergoing screening, as well as the use of dedicated breast MRI 269 
sequences outside WBMRI.  270 
 271 
Brain malignancies represent an important feature of LFS. Twelve of 13 cohorts 272 
included the brain as a routine part of the WBMRI protocol. In this meta-analysis, 273 
brain tumors appeared more common in children and young adults. Of 6 brain tumors 274 
identified by WBMRI, 5 were observed in children, and one in a 33 year old woman 275 
(Table 1). We attempted to determine the ability of the dedicated brain component of 276 
WBMRI in identifying brain tumors. We compared the outcomes of WBMRI with the 277 
dedicated brain MRI where such comparisons were available (Table 2 in the 278 
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Supplement). Of 10 brain tumors identified in individuals undergoing both WBMRI 279 
as well as a dedicated brain MRI, only 5 were identified by the WBMRI while the 280 
remainder were all identified on dedicated brain MRI but not the WBMRI. Of the 5 281 
brain tumors that were missed on WBMRI, none of the scans utilised contrast.  282 
 283 
DISCUSSION 284 
This meta-analysis provides the first statistically robust estimate of the potential 285 
clinical utility of WBMRI in screening TP53 mutation carriers. Overall, one in 14 286 
participants undergoing their first WBMRI were found to have a primary malignancy, 287 
which was then treated with curative intent. The rate of detection of localized 288 
malignancies was remarkably consistent between individual cohorts, which were 289 
conducted across 6 countries and 13 institutions. The rate at which cancers are 290 
identified appears highest in children, and lowest in young adults, and rises again in 291 
older adults. The spectrum of cancers clearly shifts with age, with a greater number of 292 
brain tumors and bone sarcomas in children, and a range of epithelial malignancies in 293 
older adults. All screen-detected cancers were treated with curative intent, although 294 
the follow up of those participants in whom cancers were identified and treated 295 
curatively is too short to assess long term outcomes. WBMRI does not reliably 296 
identify brain tumours in TP53 mutation carriers. Another important outcome of 297 
WBMRI is the detection of benign but clinically significant lesions that are medically 298 
actionable, for example by causing organ damage through local growth or undergoing 299 
malignant transformation in this high risk population.  300 
 301 
The absence of breast cancers in this screened population was notable. Breast cancer 302 
is the most common diagnosis amongst women with TP53 mutations under the age of 303 
 14 
40 years 
8
 but only two were identified in this meta-analysis (both over 40 years of 304 
age). This may reflect the high percentage of women who had undergone either 305 
unilateral or bilateral mastectomy prior to study entry (48%), inability of WBMRI to 306 
detect small breast lesions, or perhaps the routine use of dedicated breast MRI in 307 
women at high risk of breast cancer.  308 
 309 
To put the results of this meta-analysis of WBMRI in TP53 mutation carriers into the 310 
context of current clinical genetics practice, we compared these results to those 311 
achieved through screening using dedicated breast MRI in women at high risk of 312 
breast cancer due to germline BRCA1/2 mutations. Breast MRI is widely approved, 313 
recommended and reimbursed for early detection of cancer in women at high risk of 314 
breast cancer.
14-16
 The Ontario Breast Screening Program screened 2,207 women at 315 
high risk of breast cancer using either mammography or breast MRI. The detection 316 
rate from breast MRI was 1% in this series,
26
 consistent with previous large-scale 317 
studies.
27,28
 The rate of screen-detected cancers in other series was similar.
29
 318 
However, specific incidence rates for TP53 mutation carriers can be as high as 319 
4.4%,
30
 and are often detected with pre-malignant comedo DCIS histology.
30
  320 
 321 
An important aspect of population screening is the false positive rate, since the 322 
investigation of lesions that subsequently turn out to be clinically insignificant is a 323 
source of potential psychological distress, medical morbidity, and cost. Almost one in 324 
three participants in this WBMRI meta-analysis were found to have an investigable 325 
lesion, and nearly one in five lesions (18%) turned out to be both malignant and 326 
appropriately treated with curative intent. Again, comparison with breast MRI is 327 
useful. The false positive rate for the combination of breast MRI with mammography 328 
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is variably reported as between 4-30%,
27-29
 lower than that observed in our series 329 
(43%). Importantly, a recent report on the acceptability of WBMRI in the LFS 330 
population observed that screening reduces anxiety for subjects and may provide 331 
psychological benefit.
20
   332 
 333 
There are important limitations and unanswered questions arising from this study. 334 
There was heterogeneity amongst the surveillance protocols utilised in each cohort. 335 
Subgroup meta-analyses such as these can be challenging to interpret, as the meta-336 
analysis estimates are calculated incorporating estimated weights for each cohort 337 
rather than by simply pooling data across studies. Weighting is a critically valuable 338 
part of meta-analyses, as it reduces the influence of cohorts with small amounts of 339 
data while still including them in the aggregated analysis. Incorporation of study 340 
weights calculated independently in each subgroup or combined analysis may lead to 341 
situations such as our observation that cancer diagnosis rates in the aggregate of 18-40 342 
year old participants is lower for males and females combined than for either alone.  343 
 344 
Other important questions include the optimal use of WBMRI in relation to 345 
participant age and gender, since the nature and incidence of cancers varies 346 
substantially in TP53 mutation carriers. The notable excess of females to males in our 347 
study may be due to the greater engagement of females in health care.
31
 Additionally, 348 
it is unclear when WBMRI or other components of a surveillance program ought to be 349 
introduced as part of follow up for patients with an existing cancer diagnosis. Most 350 
cohorts contributing to this study did not use contrast, however the question of the 351 
importance of contrast as an effective component of a WBMRI protocol remains 352 
open. Careful follow up will be required to fully document any safety issues 353 
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associated with WBMRI screening. There is much scope for optimization of WBMRI 354 
protocols with faster acquisition sequences and improved imaging technologies. 355 
Within this meta-analysis, individual cohorts varied widely in eligibility criteria for 356 
time since curative treatment for a previous cancer, although only 7 malignancies 357 
detected by WBMRI were recurrences of previous malignancies.  358 
 359 
Finally, it is not possible to estimate the false negative rate for WBMRI from our data, 360 
since this meta-analysis describes the results of a single, baseline scan. Only follow 361 
up will determine whether occult cancers were missed by WBMRI. Longitudinal 362 
follow up of TP53 mutation carriers is very limited as there has been only one study 363 
reported to date
17
.  Longer-term follow-up of these patients will be essential to reveal 364 
the rate of cancer development in these cohorts, identify the optimal scheduling of 365 
WBMRI, and show whether early detection of cancers in TP53 mutation carriers will 366 
translate into decreased morbidity and better survival. Estimates of the cost-367 
effectiveness of WBMRI also lie beyond the scope of the current study, but will be 368 
important to implementation in clinical practice. 369 
 370 
CONCLUSION 371 
Cancer screening in germline TP53 mutation carriers is especially challenging 372 
because of the wide spectrum of associated malignancies. Baseline WBMRI identified 373 
a new and treatable malignancy in up to 7% of TP53 mutation carriers, confirming 374 
that this modality enables clinically useful early detection of cancer in this highly 375 
cancer-prone population across a broad range of health systems. The meta-analysis 376 
presented here suggest that WBMRI adds significantly to the armamentarium 377 
available to clinicians seeking to improve the likelihood of early tumor detection and 378 
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subsequent improved outcomes. Although further research will be required, our 379 
findings suggest that WBMRI may be a useful component of the routine baseline 380 
assessment of TP53 mutation carriers, in children and adults. 381 
 382 
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FIGURE LEGENDS 521 
Figure 1. Flowchart of disposition of participants. *Investigable were defined as 522 
those which required any intervention (e.g., further imaging, or biopsy). 
¶
Neoplasms 523 
were identified following biopsy in all but four cases of glioma or astrocytoma, where 524 
the diagnosis was established on imaging alone. 
§
The total number of individuals in 525 
whom a benign or malignant neoplasm was identified includes two individuals in 526 
whom two cancers were diagnosed, including one localized primary cancer, and one 527 
recurrent cancer; and one individual in whom two new primary cancers were 528 
diagnosed. 529 
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Table 1. New localised primary malignancies detected by WBMRI  547 
Age 
group 
(yr) 
Gender Morphology and Topography (age at diagnosis, yrs) 
0-17 Male Adrenocortical carcinoma (2) 
  Osteosarcoma, leg (9) 
  Low grade glioma* (15) 
  Osteosarcoma, fibula (12) 
 Female Choroid plexus carcinoma (4) 
  Low grade glioma* (6) 
  Low grade glioma* (13) 
  Osteosarcoma, chest (13) 
  Astrocytoma (13) 
  Papillary thyroid cancer (17) 
  Renal carcinoma (17) 
  Spinal chordoma (17) 
18-40 Male Osteosarcoma, rib (29) 
  Colorectal cancer (21) 
  Osteosarcoma, rib (29) 
 Female Renal and liver epithelioid angiomyolipomas (24) 
  Chondrosarcoma, sacroiliac joint (29) 
  Undifferentiated pleomorphic sarcoma, shoulder (30) 
  Astrocytoma (33) 
  Chordoma, clivus (40) 
  Thyroid carcinoma (40) 
>40 Male Prostate adenocarcinoma (41) 
  Prostate adenocarcinoma (46) 
  Lung adenocarcinoma (54) 
  Leiomyosarcoma, bowel (63) 
 Female Low grade spindle cell sarcoma, chest (41) 
  Lung adenocarcinoma (54) 
  Chromophobe renal cell carcinoma & uterine leiomyosarcoma 
(45) 
  Ductal carcinoma in situ, breast (49) 
  Abdominal myxosarcoma (51) 
  Well differentiated liposarcoma, lumbar region (52) 
  Lung adenocarcinoma (64) 
  Invasive ductal carcinoma, breast (66) 
  Lung adenocarcinoma (43) 
*Currently under surveillance with short interval MRI, with the intent to resect at a later stage 548 
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